Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.2M Buy
48,286
+44,291
+1,109% +$9.53M 1.28% 15
2026
Q1
$869K Sell
3,995
-872
-18% -$193K 0.28% 70
2025
Q4
$1.11M Buy
4,867
+161
+3% +$36.7K 0.31% 64
2025
Q3
$1.09M Buy
4,706
+78
+2% +$15.9K 0.38% 56
2025
Q2
$859K Buy
4,628
+290
+7% +$53.9K 0.32% 67
2025
Q1
$909K Buy
4,338
+2,071
+91% +$403K 0.4% 50
2024
Q4
$403K Sell
2,267
-573
-20% -$105K 0.25% 59
2024
Q3
$561K Buy
+2,840
New +$530K 0.31% 65

Other funds holding ABBV

Elyxium Wealth's ABBV Position: Q2 2026 in Review

Elyxium Wealth increased its AbbVie (ABBV) stake by 1,109% in Q2 2026, buying an estimated $9.53M and bringing the position to 48,286 shares worth $12.2M. The position accounts for 1.28% of the portfolio, ranked #15.

Elyxium Wealth first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Elyxium Wealth held 48,286 shares of AbbVie worth $12.2M as of Q2 2026.
  • Elyxium Wealth bought 44,291 AbbVie shares in Q2 2026, an estimated $9.53M.
  • AbbVie made up 1.28% of Elyxium Wealth's portfolio in Q2 2026, its #15 holding.
  • Elyxium Wealth first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Elyxium Wealth's 13F filing for Q2 2026, filed 3 Aug 2026.